BGB Securities Maintains a 'Buy' on MFA Financial (MFA); Strong Cash Yield & Price Appreciation
MFA Hot Sheet
Rating Summary:3 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
BGB Securities maintains a 'Buy' on MFA Financial Corp. (NYSE: MFA). Price target increased from $6.90 to $7.50.
BGB analyst says, "MFA announced a 14% increase in its quarterly dividend, from $0.22 in 1Q09 to $0.25 in 2Q09. We had estimated that MFA would reach this run rate during 3Q09, but market trends were evidently more favorable during the quarter than we had conservatively estimated. We are increasing our earnings estimate for 2009 from $0.95 to $1.00 per share, based on the evidence from the dividend announcement for the second quarter which exceeded our expectations by $0.02 per share...We recommend the shares based on a strong cash yield and the potential for relatively modest price appreciation."
To see more analyst ratings on MFA Click Here.
MFA Financial, Inc., formerly MFA Mortgage Investments, Inc. is a real estate investment trust primarily engaged in the business of investing, on a leveraged basis, in mortgage-backed securities (MBS).
BGB analyst says, "MFA announced a 14% increase in its quarterly dividend, from $0.22 in 1Q09 to $0.25 in 2Q09. We had estimated that MFA would reach this run rate during 3Q09, but market trends were evidently more favorable during the quarter than we had conservatively estimated. We are increasing our earnings estimate for 2009 from $0.95 to $1.00 per share, based on the evidence from the dividend announcement for the second quarter which exceeded our expectations by $0.02 per share...We recommend the shares based on a strong cash yield and the potential for relatively modest price appreciation."
To see more analyst ratings on MFA Click Here.
MFA Financial, Inc., formerly MFA Mortgage Investments, Inc. is a real estate investment trust primarily engaged in the business of investing, on a leveraged basis, in mortgage-backed securities (MBS).
You May Also Be Interested In
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
- Barclays Lowers Estimates on Tiffany & Co. (TIF); Still Sees Significant Value
- Canaccord Genuity Maintains a 'Buy' on Teva Pharma (TEVA); Adjusting Estimates; Copaxone Still In Focus
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Dividend, Life, Style and Real EstateSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
